PajtlerKWWittHSillM, et al.Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell. 2015;27(5):728-743. doi:10.1016/j.ccell.2015.04.002
2.
LouisDNPerryAWesselingP, et al.The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro-Oncol. 2021;23(8):1231-1251. doi:10.1093/neuonc/noab106
3.
GessiMCapperDSahmF, et al.Evidence of H3 K27M mutations in posterior fossa ependymomas. Acta Neuropathol (Berl). 2016;132(4):635-637. doi:10.1007/s00401-016-1608-3
4.
RyallSGuzmanMElbabaaSK, et al.H3 K27M mutations are extremely rare in posterior fossa group A ependymoma. Childs Nerv Syst. 2017;33(7):1047-1051. doi:10.1007/s00381-017-3481-3
5.
MarietCCastelDGrillJ, et al.Posterior fossa ependymoma H3 K27-mutant: an integrated radiological and histomolecular tumor analysis. Acta Neuropathol Commun. 2022;10(1):137. doi:10.1186/s40478-022-01442-4
6.
NambirajanASharmaARajeshwariM, et al.EZH2 Inhibitory protein (EZHIP/Cxorf67) expression correlates strongly with H3K27me3 loss in posterior fossa ependymomas and is mutually exclusive with H3K27M mutations. Brain Tumor Pathol. 2021;38(1):30-40. doi:10.1007/s10014-020-00385-9
7.
PajtlerKWWenJSillM, et al.Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. Acta Neuropathol (Berl). 2018;136(2):211-226. doi:10.1007/s00401-018-1877-0
8.
TanrıkuluBDanyeliAEÖzekMM. Is H3K27me3 status really a strong prognostic indicator for pediatric posterior fossa ependymomas? A single surgeon, single center experience. Childs Nerv Syst. 2020;36(5):941-949. doi:10.1007/s00381-020-04518-5
